Literature DB >> 21316706

Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance.

Chuan-Hai Zhang1, Ge-Liang Xu, Wei-Dong Jia, Jian-Sheng Li, Jin-Liang Ma, Wei-Hua Ren, Yong-Sheng Ge, Ji-Hai Yu, Wen-Bin Liu, Wei Wang.   

Abstract

BACKGROUND: To examine the expression of signal transducer and activator of transcription 3 (STAT3) and its activated form (p-STAT3), Twist, and E-cadherin in hepatocellular carcinoma (HCC), and explore their correlations with HCC progression and prognosis.
MATERIALS AND METHODS: The expression profiles of STAT3, p-STAT3, Twist, and E-cadherin were assessed on 100 clinical HCC samples and 10 normal liver tissues by using an immunohistochemical staining method, and their correlations with clinicopathologic parameters and survival of HCC patients were statistically analyzed.
RESULTS: The results demonstrated that the positive rate of STAT3, p-STAT3, and Twist in HCC was significantly higher than that in normal liver tissues; furthermore, 52% of HCC lesions showed reduced E-cadherin expression. Correlation analysis indicated that p-STAT3 was positively correlated with Twist expression, whereas Twist was negatively correlated with E-cadherin expression; p-STAT3, Twist, or E-cadherin expression was significantly associated with HCC invasion and metastasis. Survival analysis showed that HCC patients with p-STAT3, Twist positive expression, or reduced E-cadherin expression had a significantly shorter survival duration than those with p-STAT3, Twist negative expression, or those with normal E-cadherin expression. Multivariate analysis identified p-STAT3, Twist, or E-cadherin expression as an independent prognostic factor for overall survival of HCC patients after surgery.
CONCLUSIONS: By this study, we suggest that activated STAT3 signal may associate with Twist and E-cadherin expression and mediate HCC invasiveness and metastasis; abnormal p-STAT3/Twist/E-cadherin signal axis may predict poor prognosis of HCC patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21316706     DOI: 10.1016/j.jss.2010.10.030

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  23 in total

Review 1.  Twist in hepatocellular carcinoma: pathophysiology and therapeutics.

Authors:  Hui Zou; Xing Feng; Jian-Guo Cao
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

2.  Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells.

Authors:  Seog-Young Kim; Jin Wook Kang; Xinxin Song; Bo Kyoung Kim; Young Dong Yoo; Yong Tae Kwon; Yong J Lee
Journal:  Cell Signal       Date:  2013-01-16       Impact factor: 4.315

Review 3.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

Review 4.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

5.  Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.

Authors:  Carolin Ploeger; Nina Waldburger; Angelika Fraas; Benjamin Goeppert; Stefan Pusch; Kai Breuhahn; Xin Wei Wang; Peter Schirmacher; Stephanie Roessler
Journal:  Hepatology       Date:  2016-07-15       Impact factor: 17.425

6.  From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms.

Authors:  Marion Martin; Zdenko Herceg
Journal:  Genome Med       Date:  2012-01-31       Impact factor: 11.117

Review 7.  Prognostic Role of Phospho-STAT3 in Patients with Cancers of the Digestive System: A Systematic Review and Meta-Analysis.

Authors:  Mu-xing Li; Xin-yu Bi; Zhen Huang; Jian-jun Zhao; Yue Han; Zhi-Yu Li; Ye-fan Zhang; Yuan Li; Xiao Chen; Xu-hui Hu; Hong Zhao; Jian-qiang Cai
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

8.  Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Aritro Nath; Irene Li; Lewis R Roberts; Christina Chan
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

9.  Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways.

Authors:  Xiaofeng Dong; Rui Li; Peng Xiu; Xuesong Dong; Zongzhen Xu; Bo Zhai; Feng Liu; Hongchi Jiang; Xueying Sun; Jie Li; Haiquan Qiao
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

10.  Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.

Authors:  Yonggang Wang; Felix H Shek; Kwong F Wong; Ling Xiao Liu; Xiao Qian Zhang; Yi Yuan; Ester Khin; Mei-Yu Hu; Jian Hua Wang; Ronnie T P Poon; Wanjin Hong; Nikki P Lee; John M Luk
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.